In vitro efficacy of fosfomycin-containing regimens against methicillin-resistant Staphylococcus aureus in biofilms
Objectives To compare the in vitro antibacterial efficacy of antistaphylococcal antibiotics in combination with fosfomycin or rifampicin, using a biofilm model. Methods The antibacterial activities of fusidic acid, linezolid, vancomycin, teicoplanin, rifampicin, minocycline, fosfomycin and tigecycli...
Gespeichert in:
| Veröffentlicht in: | Journal of antimicrobial chemotherapy 2012-04, Vol.67 (4), p.944-950 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 950 |
|---|---|
| container_issue | 4 |
| container_start_page | 944 |
| container_title | Journal of antimicrobial chemotherapy |
| container_volume | 67 |
| creator | Tang, Hung-Jen Chen, Chi-Chung Cheng, Kuo-Chen Toh, Han-Siong Su, Bo-An Chiang, Shyh-Ren Ko, Wen-Chien Chuang, Yin-Ching |
| description | Objectives
To compare the in vitro antibacterial efficacy of antistaphylococcal antibiotics in combination with fosfomycin or rifampicin, using a biofilm model.
Methods
The antibacterial activities of fusidic acid, linezolid, vancomycin, teicoplanin, rifampicin, minocycline, fosfomycin and tigecycline, individually and in fosfomycin or rifampicin combinations, were measured against planktonic or biofilm-embedded methicillin-resistant Staphylococcus aureus (MRSA) with susceptible and resistant breakpoint concentrations (SBCs and RBCs, respectively), using the MTT-staining method and by counting the number of cfu in the biofilms.
Results
Linezolid alone at its SBC, and fosfomycin, linezolid, minocycline and tigecycline at their RBCs, exhibited killing effects on biofilm-embedded MRSA (P |
| doi_str_mv | 10.1093/jac/dkr535 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_927988579</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/jac/dkr535</oup_id><sourcerecordid>1008844319</sourcerecordid><originalsourceid>FETCH-LOGICAL-c442t-f76f3a4a29a689ecd0dedb095546115c9edd0e19461f64950ca5c551d558014b3</originalsourceid><addsrcrecordid>eNp90U1rGzEQBmARWho37SU_IIhCaClsM1p9eHUMoR-BQA9tz4s8KzlydiVH0hb876NgN4EechpGPLxieAk5ZfCFgeYXG4MXw12SXB6RBRMKmhY0e0UWwEE2SyH5MXmb8wYAlFTdG3Lctq3sNGcLkq8D_etLitQ659HgjkZHXcwuTjv0ocEYivHBhzVNdu0nGzI16_qSC51sufXox7G6ZLPPxYRCfxWzvd2NESPiXPGcbB0-0JWPzo9TfkdeOzNm-_4wT8ifb19_X_1obn5-v766vGlQiLY0bqkcN8K02qhOWxxgsMMKtJRCMSZR22EAy3TdnBJaAhqJUrJByg6YWPET8nGfu03xfra59JPPaMfRBBvn3Ot2qbtOLnWVn16UDKDrhODskX74j27inEK9o-ZpzUC1oqLPe4Qp5pys67fJTybtalL_2FlfO-v3nVV8dkicV5Mdnui_kio4PwCT0YwumYA-PzupeD0Enl2cty99-AAxS62k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>929910624</pqid></control><display><type>article</type><title>In vitro efficacy of fosfomycin-containing regimens against methicillin-resistant Staphylococcus aureus in biofilms</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Tang, Hung-Jen ; Chen, Chi-Chung ; Cheng, Kuo-Chen ; Toh, Han-Siong ; Su, Bo-An ; Chiang, Shyh-Ren ; Ko, Wen-Chien ; Chuang, Yin-Ching</creator><creatorcontrib>Tang, Hung-Jen ; Chen, Chi-Chung ; Cheng, Kuo-Chen ; Toh, Han-Siong ; Su, Bo-An ; Chiang, Shyh-Ren ; Ko, Wen-Chien ; Chuang, Yin-Ching</creatorcontrib><description>Objectives
To compare the in vitro antibacterial efficacy of antistaphylococcal antibiotics in combination with fosfomycin or rifampicin, using a biofilm model.
Methods
The antibacterial activities of fusidic acid, linezolid, vancomycin, teicoplanin, rifampicin, minocycline, fosfomycin and tigecycline, individually and in fosfomycin or rifampicin combinations, were measured against planktonic or biofilm-embedded methicillin-resistant Staphylococcus aureus (MRSA) with susceptible and resistant breakpoint concentrations (SBCs and RBCs, respectively), using the MTT-staining method and by counting the number of cfu in the biofilms.
Results
Linezolid alone at its SBC, and fosfomycin, linezolid, minocycline and tigecycline at their RBCs, exhibited killing effects on biofilm-embedded MRSA (P < 0.0001). Of the eight fosfomycin combinations studied, fosfomycin combined with linezolid, minocycline, vancomycin or teicoplanin at their respective SBCs, exhibited enhanced antibacterial activities (P < 0.0001) when compared with the control group, and outperformed rifampicin combinations (P < 0.01). The killing effects of fosfomycin combinations at their respective RBCs were better than those at their respective SBCs (P < 0.05). Significantly enhanced killing effects were observed with fosfomycin in combination with vancomycin or teicoplanin, compared with vancomycin or teicoplanin alone. For 10 randomly selected MRSA isolates, the results of colony counting in biofilms were comparable with those of the MTT-staining method.
Conclusions
Fosfomycin enhanced the activities of linezolid, minocycline, vancomycin and teicoplanin. These combinatorial treatments were even better than rifampicin combination regimens, and may provide therapeutic advantages in catheter-related or prosthetic joint infections.</description><identifier>ISSN: 0305-7453</identifier><identifier>EISSN: 1460-2091</identifier><identifier>DOI: 10.1093/jac/dkr535</identifier><identifier>PMID: 22258931</identifier><identifier>CODEN: JACHDX</identifier><language>eng</language><publisher>Oxford: Oxford University Press</publisher><subject>Anti-Bacterial Agents - pharmacology ; Antibiotics ; Antibiotics. Antiinfectious agents. Antiparasitic agents ; Bacterial diseases ; Biofilms ; Biofilms - drug effects ; Biological and medical sciences ; Drug Interactions ; Drug resistance ; Fosfomycin - pharmacology ; Human bacterial diseases ; Humans ; Infectious diseases ; Medical sciences ; Medical treatment ; Methicillin-Resistant Staphylococcus aureus - drug effects ; Methicillin-Resistant Staphylococcus aureus - physiology ; Microbial Sensitivity Tests ; Microbial Viability - drug effects ; Pharmacology. Drug treatments ; Rifampin - pharmacology ; Staining and Labeling - methods ; Staphylococcal infections, streptococcal infections, pneumococcal infections ; Staphylococcus aureus ; Staphylococcus infections ; Tetrazolium Salts - metabolism ; Thiazoles - metabolism</subject><ispartof>Journal of antimicrobial chemotherapy, 2012-04, Vol.67 (4), p.944-950</ispartof><rights>The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com 2012</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Oxford Publishing Limited(England) Apr 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c442t-f76f3a4a29a689ecd0dedb095546115c9edd0e19461f64950ca5c551d558014b3</citedby><cites>FETCH-LOGICAL-c442t-f76f3a4a29a689ecd0dedb095546115c9edd0e19461f64950ca5c551d558014b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,1579,27905,27906</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25637980$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22258931$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tang, Hung-Jen</creatorcontrib><creatorcontrib>Chen, Chi-Chung</creatorcontrib><creatorcontrib>Cheng, Kuo-Chen</creatorcontrib><creatorcontrib>Toh, Han-Siong</creatorcontrib><creatorcontrib>Su, Bo-An</creatorcontrib><creatorcontrib>Chiang, Shyh-Ren</creatorcontrib><creatorcontrib>Ko, Wen-Chien</creatorcontrib><creatorcontrib>Chuang, Yin-Ching</creatorcontrib><title>In vitro efficacy of fosfomycin-containing regimens against methicillin-resistant Staphylococcus aureus in biofilms</title><title>Journal of antimicrobial chemotherapy</title><addtitle>J Antimicrob Chemother</addtitle><description>Objectives
To compare the in vitro antibacterial efficacy of antistaphylococcal antibiotics in combination with fosfomycin or rifampicin, using a biofilm model.
Methods
The antibacterial activities of fusidic acid, linezolid, vancomycin, teicoplanin, rifampicin, minocycline, fosfomycin and tigecycline, individually and in fosfomycin or rifampicin combinations, were measured against planktonic or biofilm-embedded methicillin-resistant Staphylococcus aureus (MRSA) with susceptible and resistant breakpoint concentrations (SBCs and RBCs, respectively), using the MTT-staining method and by counting the number of cfu in the biofilms.
Results
Linezolid alone at its SBC, and fosfomycin, linezolid, minocycline and tigecycline at their RBCs, exhibited killing effects on biofilm-embedded MRSA (P < 0.0001). Of the eight fosfomycin combinations studied, fosfomycin combined with linezolid, minocycline, vancomycin or teicoplanin at their respective SBCs, exhibited enhanced antibacterial activities (P < 0.0001) when compared with the control group, and outperformed rifampicin combinations (P < 0.01). The killing effects of fosfomycin combinations at their respective RBCs were better than those at their respective SBCs (P < 0.05). Significantly enhanced killing effects were observed with fosfomycin in combination with vancomycin or teicoplanin, compared with vancomycin or teicoplanin alone. For 10 randomly selected MRSA isolates, the results of colony counting in biofilms were comparable with those of the MTT-staining method.
Conclusions
Fosfomycin enhanced the activities of linezolid, minocycline, vancomycin and teicoplanin. These combinatorial treatments were even better than rifampicin combination regimens, and may provide therapeutic advantages in catheter-related or prosthetic joint infections.</description><subject>Anti-Bacterial Agents - pharmacology</subject><subject>Antibiotics</subject><subject>Antibiotics. Antiinfectious agents. Antiparasitic agents</subject><subject>Bacterial diseases</subject><subject>Biofilms</subject><subject>Biofilms - drug effects</subject><subject>Biological and medical sciences</subject><subject>Drug Interactions</subject><subject>Drug resistance</subject><subject>Fosfomycin - pharmacology</subject><subject>Human bacterial diseases</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Medical sciences</subject><subject>Medical treatment</subject><subject>Methicillin-Resistant Staphylococcus aureus - drug effects</subject><subject>Methicillin-Resistant Staphylococcus aureus - physiology</subject><subject>Microbial Sensitivity Tests</subject><subject>Microbial Viability - drug effects</subject><subject>Pharmacology. Drug treatments</subject><subject>Rifampin - pharmacology</subject><subject>Staining and Labeling - methods</subject><subject>Staphylococcal infections, streptococcal infections, pneumococcal infections</subject><subject>Staphylococcus aureus</subject><subject>Staphylococcus infections</subject><subject>Tetrazolium Salts - metabolism</subject><subject>Thiazoles - metabolism</subject><issn>0305-7453</issn><issn>1460-2091</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp90U1rGzEQBmARWho37SU_IIhCaClsM1p9eHUMoR-BQA9tz4s8KzlydiVH0hb876NgN4EechpGPLxieAk5ZfCFgeYXG4MXw12SXB6RBRMKmhY0e0UWwEE2SyH5MXmb8wYAlFTdG3Lctq3sNGcLkq8D_etLitQ659HgjkZHXcwuTjv0ocEYivHBhzVNdu0nGzI16_qSC51sufXox7G6ZLPPxYRCfxWzvd2NESPiXPGcbB0-0JWPzo9TfkdeOzNm-_4wT8ifb19_X_1obn5-v766vGlQiLY0bqkcN8K02qhOWxxgsMMKtJRCMSZR22EAy3TdnBJaAhqJUrJByg6YWPET8nGfu03xfra59JPPaMfRBBvn3Ot2qbtOLnWVn16UDKDrhODskX74j27inEK9o-ZpzUC1oqLPe4Qp5pys67fJTybtalL_2FlfO-v3nVV8dkicV5Mdnui_kio4PwCT0YwumYA-PzupeD0Enl2cty99-AAxS62k</recordid><startdate>20120401</startdate><enddate>20120401</enddate><creator>Tang, Hung-Jen</creator><creator>Chen, Chi-Chung</creator><creator>Cheng, Kuo-Chen</creator><creator>Toh, Han-Siong</creator><creator>Su, Bo-An</creator><creator>Chiang, Shyh-Ren</creator><creator>Ko, Wen-Chien</creator><creator>Chuang, Yin-Ching</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>NAPCQ</scope><scope>P64</scope><scope>F1W</scope><scope>H95</scope><scope>L.G</scope><scope>7X8</scope></search><sort><creationdate>20120401</creationdate><title>In vitro efficacy of fosfomycin-containing regimens against methicillin-resistant Staphylococcus aureus in biofilms</title><author>Tang, Hung-Jen ; Chen, Chi-Chung ; Cheng, Kuo-Chen ; Toh, Han-Siong ; Su, Bo-An ; Chiang, Shyh-Ren ; Ko, Wen-Chien ; Chuang, Yin-Ching</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c442t-f76f3a4a29a689ecd0dedb095546115c9edd0e19461f64950ca5c551d558014b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Anti-Bacterial Agents - pharmacology</topic><topic>Antibiotics</topic><topic>Antibiotics. Antiinfectious agents. Antiparasitic agents</topic><topic>Bacterial diseases</topic><topic>Biofilms</topic><topic>Biofilms - drug effects</topic><topic>Biological and medical sciences</topic><topic>Drug Interactions</topic><topic>Drug resistance</topic><topic>Fosfomycin - pharmacology</topic><topic>Human bacterial diseases</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Medical sciences</topic><topic>Medical treatment</topic><topic>Methicillin-Resistant Staphylococcus aureus - drug effects</topic><topic>Methicillin-Resistant Staphylococcus aureus - physiology</topic><topic>Microbial Sensitivity Tests</topic><topic>Microbial Viability - drug effects</topic><topic>Pharmacology. Drug treatments</topic><topic>Rifampin - pharmacology</topic><topic>Staining and Labeling - methods</topic><topic>Staphylococcal infections, streptococcal infections, pneumococcal infections</topic><topic>Staphylococcus aureus</topic><topic>Staphylococcus infections</topic><topic>Tetrazolium Salts - metabolism</topic><topic>Thiazoles - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tang, Hung-Jen</creatorcontrib><creatorcontrib>Chen, Chi-Chung</creatorcontrib><creatorcontrib>Cheng, Kuo-Chen</creatorcontrib><creatorcontrib>Toh, Han-Siong</creatorcontrib><creatorcontrib>Su, Bo-An</creatorcontrib><creatorcontrib>Chiang, Shyh-Ren</creatorcontrib><creatorcontrib>Ko, Wen-Chien</creatorcontrib><creatorcontrib>Chuang, Yin-Ching</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of antimicrobial chemotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tang, Hung-Jen</au><au>Chen, Chi-Chung</au><au>Cheng, Kuo-Chen</au><au>Toh, Han-Siong</au><au>Su, Bo-An</au><au>Chiang, Shyh-Ren</au><au>Ko, Wen-Chien</au><au>Chuang, Yin-Ching</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In vitro efficacy of fosfomycin-containing regimens against methicillin-resistant Staphylococcus aureus in biofilms</atitle><jtitle>Journal of antimicrobial chemotherapy</jtitle><addtitle>J Antimicrob Chemother</addtitle><date>2012-04-01</date><risdate>2012</risdate><volume>67</volume><issue>4</issue><spage>944</spage><epage>950</epage><pages>944-950</pages><issn>0305-7453</issn><eissn>1460-2091</eissn><coden>JACHDX</coden><abstract>Objectives
To compare the in vitro antibacterial efficacy of antistaphylococcal antibiotics in combination with fosfomycin or rifampicin, using a biofilm model.
Methods
The antibacterial activities of fusidic acid, linezolid, vancomycin, teicoplanin, rifampicin, minocycline, fosfomycin and tigecycline, individually and in fosfomycin or rifampicin combinations, were measured against planktonic or biofilm-embedded methicillin-resistant Staphylococcus aureus (MRSA) with susceptible and resistant breakpoint concentrations (SBCs and RBCs, respectively), using the MTT-staining method and by counting the number of cfu in the biofilms.
Results
Linezolid alone at its SBC, and fosfomycin, linezolid, minocycline and tigecycline at their RBCs, exhibited killing effects on biofilm-embedded MRSA (P < 0.0001). Of the eight fosfomycin combinations studied, fosfomycin combined with linezolid, minocycline, vancomycin or teicoplanin at their respective SBCs, exhibited enhanced antibacterial activities (P < 0.0001) when compared with the control group, and outperformed rifampicin combinations (P < 0.01). The killing effects of fosfomycin combinations at their respective RBCs were better than those at their respective SBCs (P < 0.05). Significantly enhanced killing effects were observed with fosfomycin in combination with vancomycin or teicoplanin, compared with vancomycin or teicoplanin alone. For 10 randomly selected MRSA isolates, the results of colony counting in biofilms were comparable with those of the MTT-staining method.
Conclusions
Fosfomycin enhanced the activities of linezolid, minocycline, vancomycin and teicoplanin. These combinatorial treatments were even better than rifampicin combination regimens, and may provide therapeutic advantages in catheter-related or prosthetic joint infections.</abstract><cop>Oxford</cop><pub>Oxford University Press</pub><pmid>22258931</pmid><doi>10.1093/jac/dkr535</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0305-7453 |
| ispartof | Journal of antimicrobial chemotherapy, 2012-04, Vol.67 (4), p.944-950 |
| issn | 0305-7453 1460-2091 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_927988579 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Oxford University Press Journals All Titles (1996-Current); Alma/SFX Local Collection; Free Full-Text Journals in Chemistry |
| subjects | Anti-Bacterial Agents - pharmacology Antibiotics Antibiotics. Antiinfectious agents. Antiparasitic agents Bacterial diseases Biofilms Biofilms - drug effects Biological and medical sciences Drug Interactions Drug resistance Fosfomycin - pharmacology Human bacterial diseases Humans Infectious diseases Medical sciences Medical treatment Methicillin-Resistant Staphylococcus aureus - drug effects Methicillin-Resistant Staphylococcus aureus - physiology Microbial Sensitivity Tests Microbial Viability - drug effects Pharmacology. Drug treatments Rifampin - pharmacology Staining and Labeling - methods Staphylococcal infections, streptococcal infections, pneumococcal infections Staphylococcus aureus Staphylococcus infections Tetrazolium Salts - metabolism Thiazoles - metabolism |
| title | In vitro efficacy of fosfomycin-containing regimens against methicillin-resistant Staphylococcus aureus in biofilms |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T20%3A21%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20vitro%20efficacy%20of%20fosfomycin-containing%20regimens%20against%20methicillin-resistant%20Staphylococcus%20aureus%20in%20biofilms&rft.jtitle=Journal%20of%20antimicrobial%20chemotherapy&rft.au=Tang,%20Hung-Jen&rft.date=2012-04-01&rft.volume=67&rft.issue=4&rft.spage=944&rft.epage=950&rft.pages=944-950&rft.issn=0305-7453&rft.eissn=1460-2091&rft.coden=JACHDX&rft_id=info:doi/10.1093/jac/dkr535&rft_dat=%3Cproquest_cross%3E1008844319%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=929910624&rft_id=info:pmid/22258931&rft_oup_id=10.1093/jac/dkr535&rfr_iscdi=true |